Pfizer (PFE, Financial) has announced the sale of 700 million shares in the UK-based consumer healthcare company Haleon for £2.5 billion, equivalent to approximately $3.05 billion. The American pharmaceutical giant sold these shares at 357 pence each, which represents a 2.75% discount compared to Haleon's previous closing price of 367.10 pence.
The sale was conducted through a book-building process, as disclosed by Pfizer. Following this transaction, Pfizer's ownership in Haleon's outstanding shares has decreased significantly from 15% to 7.3%.
